Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Treatment regimen

Pola-R-CHP in DLBCL

Polatuzumab vedotin instead of vincristine; IPI 2 to 5

Updated: 28 October 20261 min read3 references

Summary for doctors

  • Previously untreated DLBCL with IPI 2 to 5 [1].
  • Longer 2-year progression-free survival than R-CHOP with similar toxicity [1].

Dose and schedule

Pola-R-CHP

Diffuse large B-cell lymphoma, first line, IPI 2 to 5Cycle length: Every 21 days

Diffuse large B-cell lymphoma, first line, IPI 2 to 5

DrugDoseRouteSchedule
Cycles 1 to 6
Polatuzumab vedotin1.8 mg/kgIVDay 1
Rituximab375 mg/m²IVDay 1
Cyclophosphamide750 mg/m²IVDay 1
Doxorubicin50 mg/m²IVDay 1
Prednisone100 mgOralDays 1 to 5
Cycles 7 and 8
Rituximab375 mg/m²IVDay 1
Cycle length
Every 21 days
Duration
6 cycles, then 2 cycles of rituximab alone

As in POLARIX [1].

Dose source: [3].

Evidence: POLARIX (2022)

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Premedication and supportive care

  • Before anti-CD20 treatment: HBsAg, hepatitis B core antibody (anti-HBc) and anti-HBs; if HBsAg or anti-HBc is positive, prophylactic antiviral treatment (entecavir or tenofovir) from the start until at least 12 months after the last dose [2].
  • Primary G-CSF prophylaxis was recommended in POLARIX; antiemetics as for R-CHOP.

Monitoring and dose adjustment

  • Polatuzumab neuropathy (less than with vincristine but possible); grade 2: reduce to 1.4 mg/kg.
  • Blood counts before each cycle; baseline echocardiogram.

Main evidence

Show detailsHide

POLARIX: 2-year progression-free survival 76.7% vs 70.2% with R-CHOP; no significant difference in overall survival [1].

Related cancer types

Lymphoma

Treatment regimens (physicians)

R-CHOP regimen: dose, schedule and practical pointsABVD in Hodgkin lymphoma and AVD after a negative PETBV-AVD in advanced Hodgkin lymphomaBR regimen (bendamustine and rituximab)

Physician tools and lessons

Cumulative Anthracycline Dose and Doxorubicin EquivalentsTumour Lysis Syndrome: Cairo-Bishop Criteria and PreventionKhorana Score (Cancer-Associated Thrombosis Risk)HCT-CI Comorbidity Index Before Stem Cell TransplantationIPI, R-IPI, NCCN-IPI and CNS-IPI Calculator for DLBCLFollicular Lymphoma International Prognostic Index (FLIPI) CalculatorInternational Prognostic Score (IPS) for Advanced Hodgkin LymphomaMantle Cell Lymphoma International Prognostic Index (MIPI) CalculatorIndications for haematopoietic stem cell transplantation, donor selection and conditioningGraft-versus-host disease (GVHD): prophylaxis, grading and treatment

References

3 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaTilly H, Morschhauser F, Sehn LH, et al · N Engl J Med · 2022;386:351-363
    Study cardDOIPubMed Back to text: 1 2 3 4
  2. 2
    Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion UpdateHwang JP, Feld JJ, Hammond SP, et al · J Clin Oncol · 2020;38:3698-3715
    DOIPubMed Back to text
  3. 3
    POLIVY (POLATUZUMAB VEDOTIN) — Prescribing InformationGenentech, Inc · FDA label · 2026
    Source Back to text

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/pola-r-chp/

Related pages

27 October 2026 FOLFOX (mFOLFOX6): dose, schedule and side effects Dose and schedule of mFOLFOX6 (oxaliplatin 85, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), length of adjuvant treatment, premedication, neuropathy and dose adjustment. 27 October 2026 CAPOX (XELOX): dose, schedule and side effects Dose and schedule of CAPOX or XELOX (oxaliplatin 130 and capecitabine 1000 twice daily, days 1 to 14), length of adjuvant treatment, renal adjustment and side effects. 27 October 2026 FOLFIRI regimen: dose, schedule and side effects Dose and schedule of FOLFIRI (irinotecan 180, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), diarrhoea control, UGT1A1 and dose adjustment.